15 completed. 7 Phase 2, 4 Phase 1, 3 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 3 | Completed 3 |
| Phase 4 | 2 | Completed 2 |
Follow HAL Allergy: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM) PURETHAL Mites 50,000 AUeq/ml, Biological/Vaccine: Placebo - House Dust Mite Allergy, House Dust Mite Rhinitis | Phase 3 | Completed | HAL Allergy | 691 | 2024-09-09 | 2026-08-10 |
| HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human HAL-MRE1 - Rhinitis, Allergic, Rhinoconjunctivitis, Allergic | Phase 1 | Completed | HAL Allergy | 45 | 2018-11-21 | 2019-08-06 |
| HAL-MPE1 Safety and Tolerability Study HAL-MPE1, HAL-MPE1 placebo - Peanut Allergy | Phase 1 | Completed | HAL Allergy | 42 | 2016-12-01 | 2020-02-19 |
| Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy SUBLIVAC FIX Phleum Prat. - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | HAL Allergy | 168 | 2015-09-01 | 2019-09-13 |
| SUBLIVAC FIX Mite Mixture Dose Tolerability Study SUBLIVAC FIX Mite mixture, Placebo - House Dust Mite Allergy | Phase 1 / Phase 2 | Completed | HAL Allergy | 81 | 2015-05-01 | 2015-12-02 |
| SUBLIVAC FIX Birch Phase III Short-term Efficacy SUBLIVAC FIX Birch - Birch Pollen Induced Rhinitis/Rhinoconjunctivitis | Phase 3 | Completed | HAL Allergy | 406 | 2014-09-01 | 2016-09-23 |
| HAL-MPE1 First-in-human HAL-MPE1, Placebo - Peanut Allergy | Phase 1 | Completed | HAL Allergy | 17 | 2014-06-01 | 2015-07-10 |
| PURETHAL Birch RUSH Study PURETHAL Birch, 20.000 AUM/ml - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 4 | Completed | HAL Allergy | 120 | 2013-09-01 | 2014-04-11 |
| SUBLIVAC FIX Phleum Pratense DT/DRF SUBLIVAC FIX phleum prat., Placebo - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | HAL Allergy | 266 | 2012-09-01 | 2013-05-29 |
| SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding SUBLIVAC FIX Birch - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | HAL Allergy | 270 | 2012-07-01 | 2013-05-29 |
| PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis Placebo, PURETHAL Mites 6,667 AU/ml, PURETHAL Mites 20,000 AU/ml - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | HAL Allergy | 290 | 2011-09-01 | 2013-05-29 |
| PURETHAL Grasses Rush Study PURETHAL Grasses, 20.000 AUM/ml - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 4 | Completed | HAL Allergy | 150 | 2010-02-01 | 2012-02-10 |
| Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients PURETHAL Mites 20,000 AUeq/ml - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | HAL Allergy | 48 | 2009-08-01 | 2011-09-12 |
| SUBLIVAC® Birch PROBE Study sublingual immunotherapy - Seasonal Rhinitis and/or Rhinoconjunctivitis, Birch Pollen Allergy | Phase 2 | Completed | HAL Allergy | 74 | 2009-07-01 | 2012-02-07 |
| Twin SUBLIVAC® Grasses Clinical Efficacy Study SUBLIVAC® Grasses/Placebo treatment, SUBLIVAC® Grasses treatment, Placebo treatment - Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic | Phase 3 | Completed | HAL Allergy | 350 | 2006-09-01 | 2012-02-07 |
Rhinitis, Allergic (10) · Rhinitis, Allergic, Seasonal (3) · Dust Mite Allergy (2) · Peanut Hypersensitivity (2) · Rhinitis (2) · Conjunctivitis, Allergic (1) · Hypersensitivity (1)
Biological Products (1) · Immunotherapy (1) · Sublingual Immunotherapy (1)
Germany (10) · Poland (6) · Belgium (3) · Canada (3) · Czechia (2) · Netherlands (2) · Austria (1) · Bulgaria (1) · Denmark (1) · Latvia (1) · Lithuania (1) · Slovakia (1) · Spain (1) · United States (1)
Oliver Pfaar, MD (2) · Peter Couroux, MD (2) · Carsten Bindslev-Jensen, Prof. Dr. (1) · Claus Bachert, PhD, MD (1) · Edwin Kim, MD (1) · Hans Hoogeveen (1) · Ludger Klimek, PhD (1) · Margitta Worm, Prof.Dr.med. (1) · Oliver Pfaar, PD. Dr. med. (1) · Oliver Pfaar, Prof. Dr. (1) · R Peter, Prof.Dr.med (1) · Robert Wood, MD (1) · Scott Sicherer, MD (1)
PMID 26417901, PMID 30508538, PMID 32414772, PMID 32926419
2023 (1)